Sera Prognostics, Atreca spike after Baker Bros investments

seekingalpha

2024-01-12

Shares of Sera Prognostics (NASDAQ:SERA) and Atreca (NASDAQ:BCEL) traded higher on Thursday after hedge fund manager Baker Bros. Advisors disclosed investments in the companies.
According to 13G filings on Wednesday, the New York-based financial services firm has disclosed a passive stake of ~18% in Sera Prognostics (SERA), a Salt Lake City, Utah-based diagnostics firm focused on women's health.
Another SEC filing from Atreca (BCEL) indicated that Baker Bros.'s investment in the immunotherapy developer rose to ~20%, or ~7.7M shares, up from ~3.5M. The San Carlos, California-based nano-cap biotech develops antibody-based drugs for cancer.
According to other 13G reports filed by Baker Bros. on Wednesday, it has increased its stakes in Kymera Therapeutics (KYMR) and Replimune (REPL) to ~11% and ~16%, respectively.

More on Atreca, Sera Prognostics, etc.

Sera Prognostics: The Pregnancy Company On A Hot Streak
Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript
Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more
Sera Prognostics shares rocket 160% on PreTRM study update
Seeking Alpha’s Quant Rating on Atreca

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2402018724"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2402018724\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2402018724?lang=zh_TW&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1294384963/image_1294384963.jpg","is_english":true,"pubTime":"2024-01-12 02:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2402018724","market":"us","top_or_hot":-1,"title":"Sera Prognostics, Atreca spike after Baker Bros investments","media":"seekingalpha","content":"<html><body><ul> <li>Shares of Sera Prognostics (<span>NASDAQ:SERA</span>) and <a href=\"https://laohu8.com/S/BCEL\">Atreca</a> (<span>NASDAQ:BCEL</span>) traded higher on Thursday after hedge fund manager Baker Bros. Advisors disclosed investments in the companies.</li> <li>According to 13G filings on Wednesday, the New York-based financial services firm has disclosed a passive stake of ~18%<span> in Sera Prognostics (</span>SERA<span>), a Salt Lake City, Utah-based diagnostics firm focused on women's health.</span> </li> <li>Another SEC filing from Atreca (BCEL) indicated that Baker Bros.'s investment in the immunotherapy developer rose to ~20%, or ~7.7M shares, up from ~3.5M. The San Carlos, California-based nano-cap biotech develops antibody-based drugs for cancer.</li> <li>According to other 13G reports filed by Baker Bros. on Wednesday, it has increased its stakes in Kymera Therapeutics (KYMR) and Replimune (REPL) to ~11% and ~16%, respectively.</li> </ul> <div> <h2>More on Atreca, Sera Prognostics, etc.</h2> <ul> <li>Sera Prognostics: The Pregnancy Company On A Hot Streak</li> <li>Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript</li> <li>Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more</li> <li>Sera Prognostics shares rocket 160% on PreTRM study update</li> <li>Seeking Alpha’s Quant Rating on Atreca</li> </ul> </div></body></html>","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sera Prognostics, Atreca spike after Baker Bros investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSera Prognostics, Atreca spike after Baker Bros investments\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2024-01-12 02:08</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><ul> <li>Shares of Sera Prognostics (<span>NASDAQ:SERA</span>) and <a href=\"https://laohu8.com/S/BCEL\">Atreca</a> (<span>NASDAQ:BCEL</span>) traded higher on Thursday after hedge fund manager Baker Bros. Advisors disclosed investments in the companies.</li> <li>According to 13G filings on Wednesday, the New York-based financial services firm has disclosed a passive stake of ~18%<span> in Sera Prognostics (</span>SERA<span>), a Salt Lake City, Utah-based diagnostics firm focused on women's health.</span> </li> <li>Another SEC filing from Atreca (BCEL) indicated that Baker Bros.'s investment in the immunotherapy developer rose to ~20%, or ~7.7M shares, up from ~3.5M. The San Carlos, California-based nano-cap biotech develops antibody-based drugs for cancer.</li> <li>According to other 13G reports filed by Baker Bros. on Wednesday, it has increased its stakes in Kymera Therapeutics (KYMR) and Replimune (REPL) to ~11% and ~16%, respectively.</li> </ul> <div> <h2>More on Atreca, Sera Prognostics, etc.</h2> <ul> <li>Sera Prognostics: The Pregnancy Company On A Hot Streak</li> <li>Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript</li> <li>Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more</li> <li>Sera Prognostics shares rocket 160% on PreTRM study update</li> <li>Seeking Alpha’s Quant Rating on Atreca</li> </ul> </div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://seekingalpha.com/news/4054463-sera-prognostics-atreca-spike-baker-bros-stakes\">seekingalpha</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/4054463-sera-prognostics-atreca-spike-baker-bros-stakes","article_id":"2402018724","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1294384963/image_1294384963.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2402018724","pubTimestamp":1704996537,"columns":[],"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Shares of Sera Prognostics  and Atreca  traded higher on Thursday after hedge fund manager Baker Bros. Advisors disclosed investments in the companies. According to 13G filings on Wednesday, the New York-based financial services firm has disclosed a passive stake of ~18% in Sera Prognostics , a Salt Lake City, Utah-based diagnostics firm focused on women's health.  Another SEC filing from Atreca  indicated that Baker Bros.'s investment in the immunotherapy developer rose to ~20%, or ~7.7M shares, up from ~3.5M. The San Carlos, California-based nano-cap biotech develops antibody-based drugs for cancer. According to other 13G reports filed by Baker Bros. on Wednesday, it has increased its stakes in Kymera Therapeutics  and Replimune  to ~11% and ~16%, respectively.   More on Atreca, Sera Prognostics, etc.  Sera Prognostics: The Pregnancy Company On A Hot Streak Sera Prognostics, Inc  Q3 2023 Earnings Call Transcript Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Sera预测，贝克兄弟投资后Atreca飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.65,"BCEL":1,"MNQmain":0.6,"NQmain":0.6,"KYMR":1,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"REPL":1,"SERA":1,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Shares of Sera Prognostics (NASDAQ:SERA) and Atreca (NASDAQ:BCEL) traded higher on Thursday after hedge fund manager Baker Bros. Advisors disclosed investments in the companies. According to 13G filings on Wednesday, the New York-based financial services firm has disclosed a passive stake of ~18% in Sera Prognostics (SERA), a Salt Lake City, Utah-based diagnostics firm focused on women's health.  Another SEC filing from Atreca (BCEL) indicated that Baker Bros.'s investment in the immunotherapy developer rose to ~20%, or ~7.7M shares, up from ~3.5M. The San Carlos, California-based nano-cap biotech develops antibody-based drugs for cancer. According to other 13G reports filed by Baker Bros. on Wednesday, it has increased its stakes in Kymera Therapeutics (KYMR) and Replimune (REPL) to ~11% and ~16%, respectively.   More on Atreca, Sera Prognostics, etc.  Sera Prognostics: The Pregnancy Company On A Hot Streak Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more Sera Prognostics shares rocket 160% on PreTRM study update Seeking Alpha’s Quant Rating on Atreca","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}